Terran Biosciences Announces Acquisition of a Portfolio of Novel CNS Therapeutics from Concert Pharmaceuticals
PR94944
NEW YORK, Mar.12, 2022 /PRNewswire=KYODO JBN/--
Terran Biosciences ("Terran"), a biotech platform company dedicated to the
development of transformational therapeutics for neurological and psychiatric
diseases, has entered into an agreement with Concert Pharmaceuticals
("Concert") to acquire a portfolio of Concert's CNS therapeutics and
accompanying intellectual property.
Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg
These deuterated compounds represent next-generation therapeutics with
applications across several different psychiatric and neurological conditions.
Terran plans to quickly accelerate the development of these compounds as
important complements to a growing pipeline of both early-stage and late-stage
therapeutics and technologies in the CNS space.
"It is Terran's goal to become an industry leader in neuropsychiatry by
providing a suite of solutions for patients suffering from these diseases,
which have not had many, if any, therapeutic options historically. With this
acquisition from Concert, we get even closer to our goal," stated Dr. Sam
Clark, Chief Executive Officer at Terran.
These new chemical entities are covered by composition of matter patent
applications. Financial terms of the deal were not disclosed.
About Terran Biosciences, Inc.
Terran is a biotech platform company developing a portfolio of therapeutics and
technologies for patients with neurological and psychiatric diseases. Backed by
a number of life-science and tech investors, Terran has built a CNS-focused,
tech-enabled drug development platform, and is rapidly advancing of number of
late-stage assets, which include novel psychedelic-based therapeutics.
Terran Contact:
Investor Relations:
ir@terranbiosciences.com
Media:
info@terranbiosciences.com
Source: Terran Biosciences, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。